Truist on Axsome Therapeutics (AXSM): 'We fully expect ADA to be a significantly larger opportunity for AXS-05'
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $200.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
